American Cancer Society Lowers Colorectal Cancer Screening to Age 45, Adds Additional Testing Options in Updated Guidelines

Better Health

This change in ACS guidelines would allow approximately 21 million people more to have access to colorectal cancer screening. 

Cervical Cancer Prevention: Liquid-Based Cytology and hr-HPV Co-testing Remain the Most Effective Cervical Cancer Screening Method

Insights

In our opinion, the best evidence still supports screening with Pap and hr-HPV together to provide the best protection against cervical cancer for women ages 30 to 65.

New Lung Cancer Test to Help Physicians Choose the Best Personalized Medicine for Patients

Innovation

Quest Diagnostics and Thermo Fisher have teamed up to make the Oncomine Dx Target Test broadly accessible nationwide.

You Can Protect Women’s Access to Co-Testing (Pap and HPV together) for Cervical Cancer

Action

USPSTF Considering Changes to Cervical Cancer Screening Guidelines That May Increase Risk of a Missed Diagnosis

Patients Find Info and Support at FORCEs 10th Annual Conference

Better Health

FORCE is devoted to supporting women who may be at increased risk for breast and ovarian cancer and for men who are at increased risk for hereditary cancer.

Still image of two doctors in an office looking at a computer monitor with results of testing from IBM Watson Genomics from Quest Diagnostics.

Quest & IBM Watson Genomics: Reaching Cancer Patients No Matter Where They Live

Better Health

New commercial highlights the abilities of IBM Watson Genomics from Quest Diagnostics for clinicians and patients, no matter where they are.

The Future of Precision Medicine Begins Today

Innovation

IBM Watson Genomics from Quest Diagnostics combines genomic sequencing expertise with Watson-powered cognitive computing to inform precision treatment and clinical trial options for cancer patients.

Prostate Cancer Awareness Month: An Opportune Time to Discuss Screening

Better Health

Prostate cancer is the seconding leading cause of cancer death in U.S. men, but if diagnosed early, the five-year survival rate is almost 100 percent.